Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $18.74 in the prior trading day, Cellebrite DI Ltd (NASDAQ: CLBT) closed at $18.41, down -1.76%. In other words, the price has decreased by -$1.76 from its previous closing price. On the day, 0.6 million shares were traded. CLBT stock price reached its highest trading level at $18.7799 during the session, while it also had its lowest trading level at $18.3.
Ratios:
Our goal is to gain a better understanding of CLBT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 31.43. For the most recent quarter (mrq), Quick Ratio is recorded 2.08 and its Current Ratio is at 2.11. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Needham on March 28, 2024, Reiterated its Buy rating but revised its target price to $13.50 from $13 previously. BofA Securities Upgraded its Neutral to Buy on February 16, 2024, whereas the target price for the stock was revised from $9 to $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 04 ’25 when SHAPIRA AYALA BERLER bought 8,448 shares for $18.05 per share.
DAVID GEE bought 1,969 shares of CLBT for $33,237 on Nov 24 ’25. On Nov 21 ’25, another insider, DAVID GEE, who serves as the OFFICER of the company, bought 3,704 shares for $17.44 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLBT now has a Market Capitalization of 4500676096 and an Enterprise Value of 3978724096. As of this moment, Cellebrite’s Price-to-Earnings (P/E) ratio for their current fiscal year is 60.18, and their Forward P/E ratio for the next fiscal year is 46.59. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.67 while its Price-to-Book (P/B) ratio in mrq is 10.79. Its current Enterprise Value per Revenue stands at 8.727 whereas that against EBITDA is 55.218.
Stock Price History:
The Beta on a monthly basis for CLBT is 1.28, which has changed by -0.16394186 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, CLBT has reached a high of $26.30, while it has fallen to a 52-week low of $13.10. The 50-Day Moving Average of the stock is 3.86%, while the 200-Day Moving Average is calculated to be 6.58%.
Shares Statistics:
The stock has traded on average 1.25M shares per day over the past 3-months and 905910 shares per day over the last 10 days, according to various share statistics. A total of 239.47M shares are outstanding, with a floating share count of 114.18M. Insiders hold about 52.32% of the company’s shares, while institutions hold 46.83% stake in the company. Shares short for CLBT as of 1765756800 were 5643209 with a Short Ratio of 4.50, compared to 1763078400 on 7587560. Therefore, it implies a Short% of Shares Outstanding of 5643209 and a Short% of Float of 4.67.
Earnings Estimates
. The current rating of Cellebrite DI Ltd (CLBT) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.11, with high estimates of $0.13 and low estimates of $0.09.
Analysts are recommending an EPS of between $0.54 and $0.47 for the fiscal current year, implying an average EPS of $0.51. EPS for the following year is $0.55, with 8.0 analysts recommending between $0.61 and $0.46.
Revenue Estimates
8 analysts predict $126.07M in revenue for. The current quarter. It ranges from a high estimate of $128M to a low estimate of $123.17M. As of. The current estimate, Cellebrite DI Ltd’s year-ago sales were $109.05MFor the next quarter, 8 analysts are estimating revenue of $125.2M. There is a high estimate of $128M for the next quarter, whereas the lowest estimate is $121.87M.
A total of 8 analysts have provided revenue estimates for CLBT’s current fiscal year. The highest revenue estimate was $475M, while the lowest revenue estimate was $470.03M, resulting in an average revenue estimate of $472.92M. In the same quarter a year ago, actual revenue was $401.2MBased on 8 analysts’ estimates, the company’s revenue will be $554.5M in the next fiscal year. The high estimate is $569.1M and the low estimate is $540M.
